Purpose: This work aimed to study clinical and neonatal outcomes of embryos derived from frozen compared to fresh donor oocytes in gestational carrier cycles.
Methods: This is a retrospective cohort study using the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database between 2014 and 2015, comprising of 1284 fresh transfer cycles to gestational carrier recipients of embryos resulting from fresh (n = 1119) and vitrified/thawed (n = 165) donor oocytes. Models were adjusted for gestational carrier age, preimplantation genetic testing (PGT-A), number of embryos transferred, multiple gestation, and fetal heart reduction. As our models were part of a larger analysis, intended parent BMI, smoking status, and parity were also adjusted for, but did not influence outcomes in this analysis.
Results: There was no significant difference in probability of live birth rates when comparing embryos derived from fresh and frozen donor oocytes in gestational carrier cycles. There were also no significant differences in biochemical pregnancy losses or clinical miscarriage. There were no significant differences noted in low birthweight or high birthweight infants derived from fresh versus frozen donor oocyte after transfer into a gestational carrier.
Conclusions: The analysis of fresh and frozen donor oocytes in gestational carrier cycles provides the opportunity to assess for a possible effect of vitrification on the oocyte by controlling for differences in the uterine environment. We observed no significant differences in live birth, pregnancy loss, low birthweight or high birthweight infants when comparing fresh and frozen donor oocytes in gestational carrier cycles.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957820 | PMC |
| http://dx.doi.org/10.1007/s10815-023-03016-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Visions and repercussions of identity-release in oocyte and sperm donors : descriptive survey among gamete donors].
Gynecol Obstet Fertil Senol
December 2024
Endocrinologue-Diabétologue, chef de service d'Endocrinologie, Hôpital l'Archet, CHU Nice, 151 route de Saint Antoine de Ginestière, 06 200 NICE, France. Electronic address:
Objectives: The Bioethics Law of August 2nd, 2021 established access to origins for people conceived by gamete donation. Two years after the implementation of this disposition, what is the proportion of former gamete donors informed about access to origins, and what is their position on this matter? What could be the potential repercussions of this new law on them? .
Methods: Retrospective single-center cohort study using questionnaires Results: When former gamete donors were asked about access to origins, only 53 % of oocytes donors and 71 % of sperm donors were aware of this measure.
Efficacy of modified natural cycle vs. hormone replacement therapy in oocyte donation for recipients of advanced maternal age: a retrospective study.
J Assist Reprod Genet
December 2024
Departament of Reproductive Medicine, Instituto Bernabeu, Alicante, Spain.
Purpose: To compare the efficacy of modified natural cycle (mNC) preparation versus hormone replacement therapy (HRT) for endometrial preparation in recipients of donated oocytes, specifically focusing on pregnancy rates in women of advanced maternal age.
Methods: Retrospective multicenter analysis conducted between 2021 and 2024. It includes 220 cycles of fresh single blastocyst transfers resulting from oocyte donation.
Step-by-step hysteroscopic treatment of FIGO type 3 myoma with the cold loop technique.
Fertil Steril
December 2024
Section of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Electronic address:
Objective: To demonstrate the "cold loop technique" for the hysteroscopic treatment of FIGO type 3 myomas.
Design: Step-by-step demonstration of the technique using educative video.
Subject: A 45-year-old infertile patient with repeated oocyte donor IVF failures affected by a FIGO type 3 myoma.
Flexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial.
Hum Reprod
December 2024
Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xi'an, China.
Study Question: Are live birth rates (LBRs) per woman following flexible progestin-primed ovarian stimulation (fPPOS) treatment non-inferior to LBRs per woman following the conventional GnRH-antagonist protocol in expected suboptimal responders undergoing freeze-all cycles in assisted reproduction treatment?
Summary Answer: In women expected to have a suboptimal response, the 12-month likelihood of live birth with the fPPOS treatment did not achieve the non-inferiority criteria when compared to the standard GnRH antagonist protocol for IVF/ICSI treatment with a freeze-all strategy.
What Is Known Already: The standard PPOS protocol is effective for ovarian stimulation, where medroxyprogesterone acetate (MPA) is conventionally administered in the early follicular phase for ovulatory suppression. Recent retrospective cohort studies on donor cycles have shown the potential to prevent premature ovulation and maintain oocyte yields by delaying the administration of MPA until the midcycle (referred to as fPPOS), similar to GnRH antagonist injections.
Survival of the fittest: do low vitrified/warmed donor oocyte survival rates reflect the quality of the remaining eggs?
Fertil Steril
December 2024
Shady Grove Fertility, San Diego, California, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!